1.19Open1.03Pre Close15 Volume4.61K Open Interest7.50Strike Price1.69KTurnover154.15%IV17.17%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry1.10Extrinsic Value100Contract SizeAmericanOptions Type0.5604Delta0.1351Gamma6.67Leverage Ratio-0.0243Theta0.0020Rho3.74Eff Leverage0.0075Vega
Vir Biotechnology Stock Discussion
US FDA: Revoked Emergency Use Authorization for GSK and Vir Biotechnology's Sotrovimab as of Dec 13 - Website
*************************************
REVERSE...
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
📊⚡️📊
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
📊⚡️📊
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Phase 3 Eclipse Program to Evaluate Tobevibart and Elebsiran
No comment yet